Reset filter
Palabras clave
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

285 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility NCT00689936 Multiple Myeloma - Eligibility

- 20/09/2021 - 1 formulario, 2 itemgroups, 47 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00689936

Acute Myeloid Leukemia - Lab: Biobanking

- 20/09/2021 - 13 formularios, 1 itemgroup, 3 items, 1 idioma
Itemgroup: Cancer Biobank
Acute Myeloid Leukemia Common Data Elements Holz

Eligibility Leukemia NCT02193100

- 25/06/2020 - 1 formulario, 2 itemgroups, 15 items, 1 idioma
Itemgroups: Criteria, Exclusion Criteria
Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center; ODM derived from: https://clinicaltrials.gov/show/NCT02193100

Eligibility NCT00777998 Multiple Myeloma - Eligibility

- 16/04/2014 - 1 formulario, 2 itemgroups, 10 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00408746

Eligibility NCT00722566 Multiple Myeloma - Eligibility

- 15/04/2014 - 1 formulario, 2 itemgroups, 11 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00722566

Eligibility Multiple Myeloma NCT00083538

- 24/01/2016 - 1 formulario, 2 itemgroups, 14 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally; ODM derived from: https://clinicaltrials.gov/show/NCT00083538

Eligibility Leukemia NCT00897182

- 19/05/2018 - 1 formulario, 1 itemgroup, 11 items, 1 idioma
Itemgroup: Criteria
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00897182

EBMT Multiple Myeloma General Information - 16pp EBMT Multiple Myeloma 10PCD

- 29/06/2016 - 1 formulario, 18 itemgroups, 283 items, 1 idioma
Itemgroups: EBMT FORM GENERAL INFORMATION, PATIENT, DISEASE, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION, DISEASE STATUS AT HSCT, ADDITIONAL TREATMENT POST-HSCT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, PLASMA CELL DISORDERS (INCLUDING MULTIPLE MYELOMA), PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF RELAPSE OR PROGRESSION SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS
DOCUMENTED PATHOGENS (Use this table for guidance on the pathogens of interest) Bacteria:S. pneumoniae,OHaemophilus influenzaether gram positive (i.e.: other streptococci, staphylococci, listeria …), Other gram negative (i.e.: E. coli klebsiella, proteus, serratia, pseudomonas …), Legionella sp,Mycobacteria sp, Other Fungi:Candida sp, Aspergillus sp, Pneumocystis carinii, Other Parasites: Toxoplasma gondii, Other Viruses: HSV, VZV, EBV,CMV,HHV-6, RSV,Other respiratory virus (influenza, parainfluenza, rhinovirus),Adenovirus, HBV, HCV, HIV,Papovavirus, Parvovirus, Other

Eligibility Leukemia NCT00602693

- 28/06/2017 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00602693

Eligibility Leukemia NCT00027560

- 24/07/2016 - 1 formulario, 2 itemgroups, 16 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00027560

dbGaP phs001219 Detection of Genes Predisposing to Hematologic Malignancies - pht007857.v1.p1

- 26/04/2023 - 6 formularios, 1 itemgroup, 2 items, 1 idioma
Itemgroup: pht007857
Principal Investigator: Neil E. Caporaso, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Leukemia, Lymphocytic, Chronic, B-Cell,Hodgkin Disease,Lymphoma, Non-Hodgkin,Waldenstrom Macroglobulinemia,Leukemia, Hairy Cell,Leukemia, Myeloid, Acute,Leukemia, Myelomonocytic, Juvenile https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001219 We have been conducting genetic studies on families at high risk of different hematologic malignancies, in order to define the related tumors in the families, define precursor and other related conditions, and map and identify susceptibility genes. We have focused mainly on four types of lymphoid malignancies: chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and Waldenström macroglobulinemia (WM). A few families with a rare lymphoma subtype, hairy cell leukemia (HCL) are included. In addition, single large pedigrees with acute myeloid leukemia (AML), and juvenile myelomocytic leukemia (JMML) are included. Families are ascertained for having at least two patients with the same hematologic malignancy and are classified by the type of malignancy that predominates in the family. Multiple types of lymphoid malignancies are often found in the same family. Other data has shown that these conditions aggregate together in families. Verification of cancer diagnoses is obtained through medical records, pathology reports, and flow cytometry. Family members with precursor traits are also included, monoclonal B-cell lymphocytosis (MBL) in CLL families and IgM monoclonal gammopathy of undetermined significance (MGUS) in WM families.

pht007858.v1.p1

1 itemgroup 6 items

Eligibility

1 itemgroup 1 item

pht007859.v1.p1

1 itemgroup 3 items

pht007860.v1.p1

1 itemgroup 10 items

pht007861.v1.p1

1 itemgroup 5 items

German Myeloma Patient Outcome Scale (MyPOS) - MyPOS

- 15/03/2022 - 1 formulario, 8 itemgroups, 40 items, 1 idioma
Itemgroups: Administratative Angaben, Symptome und Nebenwirkungen - Beeinträchtigung in der letzten Woche, Beeinträchtigung durch weitere Symptome, Verlauf der letzten Woche (Teil 1), Verlauf der letzten Woche (Teil 2), Probleme und Sorgen, Sorgen und Ängste, Ausfüllen des Fragebogens
Die Nutzung des MyPOS ist kostenfrei, es wird aber eine (kostenfreie) Registrierung auf der POS-Website (www.pos-pal.org) gewünscht. Um eine Information über Nutzung und/oder Änderung wird seitens des POS-Team explizit gebeten. Affiliation: Dr. med. Christina Gerlach M.Sc. Oberärztin | Klinik für Palliativmedizin Fachärztin für Innere Medizin, Hämatologie & Onkologie; Notfallmedizin, Palliativmedizin Universitätsklinikum Heidelberg | Im Neuenheimer Feld 305 | 69120 Heidelberg Tel. +49 6221 56-310683 | Fax. +49 6221 56-7203 | E-Mail: christina.gerlach@med.uni-heidelberg.de http://www.klinikum.uni-heidelberg.de Gerlach, C., Taylor, K., Ferner, M. et al. Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer 20, 245 (2020). https://doi.org/10.1186/s12885-020-06730-7

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial